Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396357 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 914
- Enrollment target
NCT00396357: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00396357 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 914 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00396357, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 914 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of vildagliptin in combination with metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes.
Interventions
- DRUG metformin
- DRUG Vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 914 participants |
| Start Date | 2006-10 |
| Phase | Phase 3 |
What the finished NCT00396357 record still lists
NCT00396357 is an interventional study that assigns participants to a tested intervention. The registered 914 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 2 interventions - of which metformin is the first listed.
NCT00396357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00396357 about?
NCT00396357 is a clinical study titled "Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone". This study is designed to evaluate the efficacy and safety of vildagliptin in combination with metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes.
What is the current status of trial NCT00396357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 914 participants. The study started on 2006-10.
What interventions are being tested in trial NCT00396357?
The interventions under investigation include: metformin (DRUG), Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00396357?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00396357's enrollment target sits among peer trials
914 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia